Abstract:

Objective: The effect of malvidin-3-galactoside chloride (Mv-3-gal-Cl) on TNF-α-induced inflammation in
human umbilical vein endothelial cells (HUVEC) was investigated in this study. Methods: HUVEC were treated with TNF-α
(10 μg/L) alone and combined with Mv-3-gal-Cl (1, 10, 50 and 100 μmol/L), respectively. DMSO was used as control. The
soluble ICAM-1 protein content in cell supernatant was detected by ELISA. The change in ICAM-1 mRNA expression
level in cells was detected by RT-PCR. The expression of ICAM-1 and IкBα was assessed by Western blotting. The
activity of NF-кB was evaluated by immunofluorescence. Results: Mv-3-gal-Cl appeared to specifically down-regulate the
TNF-α-induced cell surface expression of ICAM-1 and ICAM-1 mRNA expression and protein release from HUVEC cells
in a concentration-dependent manner. The inhibitory effect of Mv-3-gal-Cl on protein expression might be associated with
the suppression of NF-κB in HUVECs. Conclusion: Mv-3-gal-Cl can inhibit TNF-α-induced inflammation in HUVECs. The
anti-inflammatory effect of Mv-3-gal-Cl provides a theoretical basis for preventing and treating pro-inflammatory cytokinesinduced
endothelial dysfunction and cardiovascular diseases resulting from inflammation.

Key words: malvidin-3-galactoside chloride (Mv-3-gal-Cl), human umbilical vein endothelial cell (HUVEC), tumor necrosis factor-α, inflammatory effect, intercellular cell adhesion molecule-1 (ICAM-1), NF-kappa B